Breast Cancer

Rachel A. Freedman, MD, MPH, associate clinical director, Breast Oncology Center, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute, senior physician, assistant professor of medicine, Harvard Medical School, discusses brain metastases in patients with HER2-positive breast cancer.

Jens Huober, MD, professor of gynecologic oncology, Ulm University Hospital, discusses the de-escalation of treatments for patients with breast cancer.

Gunter von Minckwitz, MD, PhD, president of the German Breast Group in Neu-Isenburg, Germany, discusses the phase III results of the APHINITY trial, which explored the addition of pertuzumab (Perjeta) to standard postoperative trastuzumab (Herceptin) therapy for patients with HER2-positive early breast cancer.

Daniel F. Hayes, MD, professor at the University of Michigan Comprehensive Cancer Center, discusses the future of biomarkers for patients with breast cancer.